Bristol Myers Squibb helped the cell encapsulation technology developer raise cash that will help fund its international growth.

TreeFrog Therapeutics, a France-based stem cell therapy developer advancing research from Digital Photonics and Nanoscience Laboratory (LP2N), completed a $75m series B round yesterday featuring pharmaceutical firm Bristol Myers Squibb.

The round was led by BPIfrance’s Large Venture fund and included investment firm Leonard Green & Partners and XAnge, the venture capital arm of private equity group Siparex.

Founded in 2018, TreeFrog has created high-throughput cell encapsulation technology dubbed C-Stem which facilitates the mass production and differentiation of stem cells…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn